Effects of clozapine treatment on the improvement of substance use disorders other than nicotine in individuals with schizophrenia spectrum disorders: A systematic review and meta-analysis
Open accessThe DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
Background: Antipsychotic medications are the mainstay of treatment for schizophrenia and are associated with a reduction in psychiatric hospitalization and overall mortality. Some evidence suggest that antipsychotic medications might have a varying effect on the improvement of comorbid substance use disorders (SUDs), with clozapine showing more favorable outcomes. Aim: We systematically reviewed all available evidence on effects of clozapine on the improvement of SUDs other than nicotine. Methods: Electronic searches of MEDLINE, Embase, PsycINFO, and CINHAL were conducted up to March 1, 2022. Studies of any methodological design involving two concepts: (1) clozapine and (2) SUD terms (excluding nicotine) were included. For SUD outcomes with three or more comparative studies with available raw data meta-analysis was performed. SUD outcomes not meeting criteria for meta-analysis were described qualitatively. Risk of bias was examined using “Downs and Black,” and “Q-Coh” instruments. Results: The majority of individuals in the included 31 studies were male and of European ancestry. Abstinence was the most common outcome. Most of the studies were of low-to-moderate quality, and none of the studies met all the quality criteria. Pooled findings from four observational studies in samples of patients with predominantly comorbid alcohol use disorder showed that clozapine treatment is associated with significantly higher odds of remaining abstinent. In addition clozapine was associated with decreased odds of psychiatric hospitalization in all but one observational study. Conclusions: Our systematic review and meta-analysis builds upon previous reviews, and it suggests the association of clozapine treatment with significantly higher odds of remaining abstinent from substance use and decreased likelihood of psychiatric hospitalization, compared with continuing treatment with other antipsychotic medications. Still, the validity of this association needs greater exploration and providing recommendations for the utility of clozapine in individuals without treatment-resistant psychosis and comorbid SUDs would be premature.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Pharmacological interventions, including medications such as clozapine, have shown promise in treating individuals with comorbid SUDs and psychiatric conditions, with research suggesting higher odds of abstinence and reduced psychiatric hospitalization”
From Navigating the Complex Intersection of Substance Use and Psychiatric Disorders: A Comprehensive Review (2024) · cites this paper as [30]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“however, the effectiveness of such treatments remains inconclusive due to limited sample sizes and insufficient reporting in randomized controlled trials”
From Navigating the Complex Intersection of Substance Use and Psychiatric Disorders: A Comprehensive Review (2024) · cites this paper as [30]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n71 · Cited by 108,283
Downs, S. H., & Black, N. (1998) · Journal of Epidemiology and Community Health · doi:10.1136/jech.52.6.377 · Cited by 8,252 · cited 1×
“We used Downs and Black instrument (Downs and Black, 1998) for RCTs, which contains 27 items for randomized and non-randomized comparative studies, providing a total score of 28 for each study.”
Method(2022) · The Lancet Psychiatry · doi:10.1016/s2215-0366(21)00395-3 · Cited by 6,481 · cited 1×
“Four observational studies (Brunette et al., 2006, 2008; Drake et al., 2000; Green et al., 2003) with available raw data reported the proportion of individuals with concurrent SSD and SUDs (predominantly alcohol) who remained abstinent (defined as either complete cessation of use or use without…”
BackgroundPRESS Peer Review of Electronic Search Strategies: 2015 Guideline Statement
McGowan, J., Sampson, M., Salzwedel, D. M., Cogo, E., Foerster, V., & Lefebvre, C. (2016) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2016.01.021 · Cited by 5,700 · cited 2×
“Systematic searches of the peerreviewed literature were conducted following PRESS guidelines (McGowan et al., 2015) in consultation with a medical librarian in four electronic databases (i.e., MEDLINE, PsycINFO, Embase, and CINAHL) from inception to March 1, 2022.”
MethodTiihonen, J., Mittendorfer-Rutz, E., Majak, M., Mehtälä, J., Hoti, F., Jedenius, E., Enkusson, D., Leval, A., Sermon, J., Tanskanen, A., et al. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.1322 · Cited by 670 · cited 1×
“Antipsychotic medications are the mainstay of treatment for schizophrenia and are associated with a reduction in psychiatric hospitalization (Tiihonen et al., 2017) and overall mortality (Taipale et al., 2018).”
BackgroundHaddaway, N. R., Grainger, M. J., & Gray, C. T. (2022) · Research Synthesis Methods · doi:10.1002/jrsm.1563 · Cited by 604 · cited 1×
“In addition, a web-based citation chaser (Haddaway et al., 2022) was used for backward and forward citation chasing for additional references not identified in our primary searches.”
MethodHunt, G. E., Large, M. M., Cleary, M., Lai, H. M. X., & Saunders, J. B. (2018) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2018.07.011 · Cited by 482 · cited 3×
“441), with trends for increased substance use over time (Hunt et al., 2018).”
BackgroundInfluentialAshok, A. H., Mizuno, Y., Volkow, N. D., & Howes, O. D. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.0135 · Cited by 330 · cited 2×
“Furthermore, as different non-prescribed substances vary in impact on the striatal dopamine system (Ashok et al., 2017; Kamp et al., 2019), comparing individuals without characterizing the type and severity of consequences of the substance(s) used may increase heterogeneity in observational studies.”
BackgroundAntipsychotics and mortality in a nationwide cohort of 29,823 patients with schizophrenia
Taipale, H., Mittendorfer-Rutz, E., Alexanderson, K., Majak, M., Mehtälä, J., Hoti, F., Jedenius, E., Enkusson, D., Leval, A., Sermon, J., et al. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2017.12.010 · Cited by 262 · cited 1×
“Antipsychotic medications are the mainstay of treatment for schizophrenia and are associated with a reduction in psychiatric hospitalization (Tiihonen et al., 2017) and overall mortality (Taipale et al., 2018).”
BackgroundWeiner, D. M., Meltzer, H. Y., Veinbergs, I., Donohue, E. M., Spalding, T. A., Smith, T. T., Mohell, N., Harvey, S. C., Lameh, J., Nash, N., et al. (2004) · Psychopharmacology · doi:10.1007/s00213-004-1940-5 · Cited by 253 · cited 1×
“…(GABA-B)-mediated inhibitory neurotransmission (Nair et al., 2020), N-desmethylclozapine’s muscarinic acetylcholine receptor M1 agonist activity (Weiner et al., 2004), and clozapine’s potent blockade of alpha-2 noradrenergic receptors coupled with an increase in norepinephrine levels (Green…”
BackgroundThe Effects of Clozapine on Alcohol and Drug Use Disorders Among Patients With Schizophrenia
Drake, R. E., Xie, H., McHugo, G. J., & Green, A. I. (2000) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033464 · Cited by 253 · cited 2×
“Four observational studies (Brunette et al., 2006, 2008; Drake et al., 2000; Green et al., 2003) with available raw data reported the proportion of individuals with concurrent SSD and SUDs (predominantly alcohol) who remained abstinent (defined as either complete cessation of use or use without impairment) on clozapin…”
BackgroundGABAB receptor agonists for the treatment of drug addiction: a review of recent findings
Cousins, M. S., Roberts, D. C. S., & Wit, H. D. (2002) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(01)00163-6 · Cited by 240 · cited 2×
“…receptors coupled with an increase in norepinephrine levels (Green et al., 2008) are not only hypothesized to be part of the mechanism of treating resistant psychosis but may also have potential roles in treating comorbid SUDs (Cousins et al., 2002; Green et al., 2008; Walker et al., 2022).”
BackgroundUnique Effects of Clozapine: A Pharmacological Perspective
Khokhar, J. Y., Henricks, A. M., Sullivan, E. D. K., & Green, A. I. (2018) · Advances in Pharmacology · doi:10.1016/bs.apha.2017.09.009 · Cited by 182 · cited 2×
“These dopaminergic pathways serve as the site of reward-based effects of addictive substances and are hypothesized to mediate motivation, pleasure, and contentment in daily life (Khokhar et al., 2017).”
BackgroundSubstance abuse and schizophrenia: Pharmacotherapeutic intervention
Green, A. I., Noordsy, D. L., Brunette, M. F., & O’Keefe, C. D. (2007) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2007.01.008 · Cited by 175 · cited 5×
“, 2008) are not only hypothesized to be part of the mechanism of treating resistant psychosis but may also have potential roles in treating comorbid SUDs (Cousins et al., 2002; Green et al., 2008; Walker et al., 2022).”
BackgroundInfluentialLimbic selectivity of clozapine
Pilowsky, L. S., Mulligan, R. S., Acton, P. D., Ell, P. J., Costa, D. C., & Kerwin, R. W. (1997) · The Lancet · doi:10.1016/s0140-6736(05)63079-6 · Cited by 173 · cited 1×
“Firstly, clozapine’s selective and relatively low occupancy in striatal dopamine type-2 receptors (Pilowski et al., 1997) may not contribute to further striatal dopaminergic downregulation and results in a low liability to cause EPS.”
BackgroundAlcohol and cannabis use in schizophrenia: effects of clozapine vs. risperidone
Green, A. I., Burgess, E. S., Dawson, R., Zimmet, S. V., & Strous, R. D. (2002) · Schizophrenia Research · doi:10.1016/s0920-9964(02)00231-1 · Cited by 162 · cited 2×
“Four observational studies (Brunette et al., 2006, 2008; Drake et al., 2000; Green et al., 2003) with available raw data reported the proportion of individuals with concurrent SSD and SUDs (predominantly alcohol) who remained abstinent (defined as either complete cessation of use or use without impairment) on clozapin…”
BackgroundCorrell, C. U., Agid, O., Crespo-Facorro, B., de Bartolomeis, A., Fagiolini, A., Seppälä, N., & Howes, O. D. (2022) · CNS Drugs · doi:10.1007/s40263-022-00932-2 · Cited by 162 · cited 1×
“Many clozapine adverse effects can be managed by proper dosing, therapeutic drug monitoring and pharmacological/nonpharmacological interventions, and they need not be a barrier for individuals with treatment-resistant SSD and SUDs (Correll et al., 2022).”
BackgroundHasan, A., Falkai, P., Wobrock, T., Lieberman, J., Glenthøj, B., Gattaz, W. F., Thibaut, F., Möller, H.-J., & on behalf of the WFSBP Task Force on Treatment Guidelines for Schizophrenia (2015) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2015.1009163 · Cited by 145 · cited 1×
“The World Federation of Societies of Biological Psychiatry guidelines (Hasan et al., 2015) recommends clozapine for schizophrenia and comorbid alcohol use disorder (Category of evidence B, level of recommendation 3).”
BackgroundBrunette, M. F., Drake, R. E., Xie, H., McHugo, G. J., & Green, A. I. (2005) · Schizophrenia Bulletin · doi:10.1093/schbul/sbl003 · Cited by 142
Glutamatergic transmission in drug reward: implications for drug addiction
D'Souza, M. S. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00404 · Cited by 142
Crockford, D., & Addington, D. (2017) · The Canadian Journal of Psychiatry · doi:10.1177/0706743717720196 · Cited by 113 · cited 3×
“More recently, the Canadian (Crockford and Addington, 2017) and Spanish (Arranz et al., 2022) guidelines for schizophrenia did not recommend using one antipsychotic over another for individuals with comorbid SUDs due to limited evidence from randomized prospective trials.”
BackgroundKrause, M., Huhn, M., Schneider-Thoma, J., Bighelli, I., Gutsmiedl, K., & Leucht, S. (2019) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2018.11.1105 · Cited by 86 · cited 1×
“A systematic review and meta-analysis of prospective randomized controlled trials (RCT) reported the effects of antipsychotics on SUD improvement in schizophrenia (Krause et al., 2019).”
BackgroundReduction of comorbid substance abuse with clozapine
Marcus, P., & Snyder, R. (1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.6.959a · Cited by 83 · cited 1×
“All the case reports/series except one (Marcus and Snyder, 1995) documented presence of treatment-resistant SSD before initiation of clozapine.”
BackgroundBinding of clozapine to the GABAB receptor: clinical and structural insights
Nair, P. C., McKinnon, R. A., Miners, J. O., & Bastiampillai, T. J. (2020) · Molecular Psychiatry · doi:10.1038/s41380-020-0709-5 · Cited by 82 · cited 2×
“Secondly, clozapine’s propensity to increase γ-aminobutyric acid-B (GABA-B)-mediated inhibitory neurotransmission (Nair et al., 2020), N-desmethylclozapine’s muscarinic acetylcholine receptor M1 agonist activity (Weiner et al.”
BackgroundChanges in Brain Glutamate on Switching to Clozapine in Treatment-Resistant Schizophrenia
McQueen, G., Sendt, K.-V., Gillespie, A. L., Avila, A., Lally, J., Vallianatou, K., Chang, N., Ferreira, D., Borgan, F., Howes, O. D., et al. (2020) · Schizophrenia Bulletin · doi:10.1093/schbul/sbaa156 · Cited by 78 · cited 1×
“Lastly, clozapine’s propensity to decrease striatal glutamate levels (McQueen et al., 2021) has potential as an anti-glutamatergic agent to attenuate rewarding effects of substance use (D’Souza, 2015).”
BackgroundSignificant interaction between clozapine and cocaine in cocaine addicts
Farren, C. K., Hameedi, F. A., Rosen, M. A., Woods, S. W., Jatlow, P. I., & Kosten, T. R. (2000) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(99)00114-3 · Cited by 71 · cited 2×
“In a phase-1 study (Farren et al., 2000) of four oral challenges with ascending doses of clozapine (12.5, 25, and 50 mg) and placebo followed 2 h later by a 2 mg/kg dose of intranasal cocaine, one participant out of eight had to be removed from the challenge study due to syncope.”
BackgroundMethodInfluentialMachielsen, M. W. J., Beduin, A. S., Dekker, N., Kahn, R. S., LINSZEN, D. H., van Os, J., Wiersma, D., Bruggeman, R., Cahn, W., de Haan, L., et al. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881111408957 · Cited by 71 · cited 1×
“One prospective cohort study (n = 123) reported reduction in craving for cannabis in clozapine-treated patients compared with risperidone-treated and olanzapine-treated patients (Machielsen et al., 2012).”
ResultSubstance use and schizophrenia: adverse correlates in the CATIE study sample
Kerfoot, K. E., Rosenheck, R. A., Petrakis, I. L., Swartz, M. S., Keefe, R. S. E., McEvoy, J. P., & Stroup, T. S. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.07.032 · Cited by 70 · cited 1×
“Email: reza.rafizadeh1@phsa.ca abstinent individuals (Kerfoot et al., 2011).”
Brunette, M. F., Dawson, R., O’Keefe, C. D., Narasimhan, M., Noordsy, D. L., Wojcik, J., & Green, A. I. (2011) · Journal of Dual Diagnosis · doi:10.1080/15504263.2011.570118 · Cited by 67
Neuroleptic Dysphoria May be the Missing Link between Schizophrenia and Substance Abuse
Voruganti, L. N. P., Heslegrave, R. J., & Awad, A. G. (1997) · The Journal of Nervous & Mental Disease · doi:10.1097/00005053-199707000-00008 · Cited by 66
Potvin, S., Pampoulova, T., Mancini-Marië, A., Lipp, O., Bouchard, R.-H., & Stip, E. (2006) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2005.079228 · Cited by 65 · cited 2×
“Furthermore, incidence of antipsychotic associated EPS may increase relapse to substance use (Potvin et al., 2006; Voruganti et al., 1997).”
BackgroundResultJarde, A., Losilla, J.-M., Vives, J., & F. Rodrigo, M. (2013) · International Journal of Clinical and Health Psychology · doi:10.1016/s1697-2600(13)70017-6 · Cited by 50 · cited 1×
“For cohort studies, we used the Quality of Cohort Studies (Q-Coh), which is a tool used to assess methodology and identify studies that would be a source of bias in the meta-analysis (Jarde et al., 2013).”
MethodKalyoncu, A., Mırsal, H., Pektaş, Ö., Ünsalan, N., Tan, D., & Beyazyürek, M. (2005) · Journal of Psychopharmacology · doi:10.1177/0269881105051542 · Cited by 47 · cited 1×
“There were four published cases on augmentation strategies of clozapine and achieving abstinence/or reduction in use in comorbid alcohol use disorder, lamotrigine n = 3 (Kalyoncu et al., 2005), and amisulpride n = 1 (Dervaux and Cazali, 2007).”
BackgroundSchnell, T., Koethe, D., Krasnianski, A., Gairing, S., Schnell, K., Daumann, J., & Gouzoulis‐Mayfrank, E. (2014) · The American Journal on Addictions · doi:10.1111/j.1521-0391.2014.12126.x · Cited by 46 · cited 1×
“The second RCT (n = 30) showed no difference between clozapine-treated versus ziprasidone-treated individuals after 12 months of follow-up with high dropout rates (Schnell et al., 2014).”
BackgroundKamp, F., Proebstl, L., Penzel, N., Adorjan, K., Ilanković, A. N., Pogarell, O. M., Koller, G., Soyka, M., Falkai, P., Koutsouleris, N., et al. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-018-0191-9 · Cited by 45 · cited 2×
“Furthermore, as different non-prescribed substances vary in impact on the striatal dopamine system (Ashok et al., 2017; Kamp et al., 2019), comparing individuals without characterizing the type and severity of consequences of the substance(s) used may increase heterogeneity in observational studies.”
BackgroundClozapine and substance abuse in patients with schizophrenia.
Ml, L., Dickson, R. A., Campbell, M., Oliphant, J., Gretton, H. M., & Dalby, J. T. (1998) · PubMed · Cited by 38
Machielsen, M. W. J., Veltman, D. J., van den Brink, W., & de Haan, L. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114527357 · Cited by 37 · cited 1×
“In another small open-label RCT (n = 28) with 4 weeks of follow-up, clozapine treatment showed significant reduction in craving for cannabis compared with risperidone (Machielsen et al., 2014).”
BackgroundArranz, B., Garriga, M., García‐Rizo, C., & San, L. (2017) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2017.12.006 · Cited by 36 · cited 3×
“In another systematic review, clozapine was inferred to be superior to firstgeneration antipsychotics (FGAs) in improving SUD and remission (Arranz et al., 2017).”
BackgroundLähteenvuo, M., Luykx, J. J., Taipale, H. T., Mittendorfer‐Rutz, E., Tanskanen, A. J., Batalla, A., & Tiihonen, J. (2022) · The British Journal of Psychiatry · doi:10.1192/bjp.2022.117 · Cited by 35 · cited 3×
“Indeed, in the only registry-based observational study (Lahteenvuo et al., 2022), the odds of decreasing psychiatric and substance use-related hospitalization were similar between clozapine and any long-acting injectable antipsychotics.”
BackgroundInfluentialSiskind, D. J., Harris, M., Phillipou, A., Morgan, V. A., Waterreus, A. J., Galletly, C. A., Carr, V. J., Harvey, C. A., & Castle, D. J. (2016) · Epidemiology and Psychiatric Sciences · doi:10.1017/s2045796016000305 · Cited by 34 · cited 2×
“The 2017 Australian National survey (Siskind et al., 2017) reported on lifetime and past year substance use in individuals with SSD (n = 1049) treated with clozapine versus other antipsychotics.”
BackgroundChiappini, S., Schifano, F., Corkery, J. M., & Guirguis, A. (2020) · Brain Sciences · doi:10.3390/brainsci10020105 · Cited by 33 · cited 2×
“Clozapine safety in individuals with comorbid SUDs A descriptive analysis of the European Medicines Agency Pharmacovigilance Database (Chiappini et al., 2020) explored cases reported due to adverse drug reactions (ADRs) related to clozapine.”
BackgroundKim, J. H., Kim, D., & Marder, S. R. (2008) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2008.01.009 · Cited by 27 · cited 1×
“Kim et al. (2008) in a prospective cohort study of patients with SSD and comorbid alcohol use disorder (n = 61) with up to 2 years follow-up after a psychiatric hospitalization in South Korea found time to rehospitalization to be significantly longer in clozapine-treated patients compared with…”
BackgroundSchizophrenia and co-occurring substance use disorder: Reward, olfaction and clozapine
Mesholam‐Gately, R. I., Gibson, L. E., Seidman, L. J., & Green, A. I. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.03.002 · Cited by 24 · cited 4×
“In another systematic review, clozapine was inferred to be superior to firstgeneration antipsychotics (FGAs) in improving SUD and remission (Arranz et al., 2017).”
BackgroundInfluentialXie, H., McHugo, G. J., & Drake, R. E. (2009) · Psychiatric Services · doi:10.1176/ps.2009.60.6.804 · Cited by 18 · cited 1×
“Use of clozapine was remarkably common (over one third) for this group (Xie et al., 2009).”
BackgroundTreating Methamphetamine-Induced Resistant Psychosis with Clozapine
Seddigh, R., Keshavarz‐Akhlaghi, A., & Shariati, B. (2014) · Case Reports in Psychiatry · doi:10.1155/2014/845145 · Cited by 14 · cited 1×
“In two cases, patients with amphetamine-type-SUD achieved remission from resistant psychosis and maintained abstinence while on clozapine (Seddigh et al., 2014).”
BackgroundTang, S., Ansarian, A., & Courtney, D. (2017) · PubMed · Cited by 13
Clozapine and Amisulpride in Refractory Schizophrenia and Alcohol Dependence
Dervaux, A., & Cazali, J. (2007) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31814cfaa9 · Cited by 11 · cited 1×
“There were four published cases on augmentation strategies of clozapine and achieving abstinence/or reduction in use in comorbid alcohol use disorder, lamotrigine n = 3 (Kalyoncu et al., 2005), and amisulpride n = 1 (Dervaux and Cazali, 2007).”
BackgroundWalker, L. C., Campbell, E. J., Huckstep, K. L., Chen, N. A., Langmead, C. J., & Lawrence, A. J. (2021) · Pharmacology Research & Perspectives · doi:10.1002/prp2.907 · Cited by 11
Feeley, R. J., Arnaout, B., & Yoon, G. (2017) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000794 · Cited by 10 · cited 1×
“Another case report (Feeley et al., 2017) described clozapine resistance, lack of improvement in SUD, and the incidence of small bowel obstruction resulting in an eventual switch to aripiprazole with clinically meaningful therapeutic outcomes.”
BackgroundArranz, B., Garriga, M., Bernardo, M., González-Pinto, A. M., Arrojo, M., Torrens, M., Tirado-Muñoz, J., Fonseca, F., Sáiz, P. A., Flórez, G., et al. (2021) · Adicciones · doi:10.20882/adicciones.1504 · Cited by 9 · cited 1×
“More recently, the Canadian (Crockford and Addington, 2017) and Spanish (Arranz et al., 2022) guidelines for schizophrenia did not recommend using one antipsychotic over another for individuals with comorbid SUDs due to limited evidence from randomized prospective trials.”
BackgroundBrunette, M. F., O’Keefe, C. D., Zimmet, S. V., Wojcik, J., Dawson, R., Brownell, E., & Green, A. I. (2008) · Journal of Dual Diagnosis · doi:10.1080/15504260802313816 · Cited by 6 · cited 1×
“Four observational studies (Brunette et al., 2006, 2008; Drake et al., 2000; Green et al., 2003) with available raw data reported the proportion of individuals with concurrent SSD and SUDs (predominantly alcohol) who remained abstinent (defined as either complete cessation of use or use without…”
BackgroundMaremmani, I., Pacini, M., Lazzeri, A., Perugi, G., & Deltito, J. A. (2006) · Addictive Disorders & Their Treatment · doi:10.1097/01.adt.0000210703.70788.65 · Cited by 6 · cited 1×
“Effects of clozapine on psychiatric hospitalization Maremmani et al. (2006) in a retrospective cohort study (n = 56) found that treatment of clozapine in patients with concurrent cannabis use disorder was associated with a shorter duration of hospitalization compared with those without concurrent…”
BackgroundYee, M. R., Espiridon, E., Oladunjoye, A. O., Millsaps, U., Harvey, N., & Vora, A. (2021) · Cureus · doi:10.7759/cureus.15238 · Cited by 5 · cited 1×
“In contrast, Yee et al. (2021) in a 10-year retrospective cohort study (n = 179) of individuals enrolled in an assertive community treatment program with primarily SSD and concurrent SUDs (not limited to alcohol), clozapine treatment was associated with increased odds of psychiatric hospitalization…”
BackgroundSubstance Abuse in Clozapine-Treated Schizophrenic Patients
Sand, P. G., & Soyka, M. (1997) · Journal of Neuropsychiatry · doi:10.1176/jnp.9.4.626-a · Cited by 3 · cited 1×
“One published case report (Sand and Soyka, 1997) described the ineffectiveness of clozapine in improving SUD and resulting in excess sedation and its eventual discontinuation.”
BackgroundPang, N. T. P., Isa, M. F. M., Singh, V. S., & Masiran, R. (2017) · BMJ Case Reports · doi:10.1136/bcr-2017-221048 · Cited by 3 · cited 1×
“There was one published case (Pang et al., 2017) of clozapine in comorbid opioid/amphetamine-type-substance co-use disorder, maintaining abstinence with daily witnessed ingestion of methadone and clozapine.”
Background
Research works printed but not linked: 1
- Brunette MF Dawson R O’Keefe CD, et al. (2011) Clozapine vs. other antipsychotics for schizophrenia and co-occurring cannabis use disorder. Schizophr Bull 37: 297.
Cited by
Bahji, A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13040999 · Cited by 83
Self-citationAgid, O., Crespo‐Facorro, B., de Bartolomeis, A., Fagiolini, A. M., Howes, O. D., Seppälä, N., & Correll, C. U. (2024) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2024.04.012 · Cited by 45
de León, J., Baldessarini, R. J., Balon, R., Bilbily, J., Caroff, S. N., Citrome, L., Correll, C. U., Cotes, R. O., Davis, J. M., DeLisi, L. E., et al. (2025) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001990 · Cited by 39
Management of schizophrenia and comorbid substance use disorders: expert review and guidance
Neyra, A., Parro-Torres, C., Ros‐Cucurull, E., Machado, I. C., Echarri, E., & Torrens, M. (2024) · Annals of General Psychiatry · doi:10.1186/s12991-024-00529-7 · Cited by 39
“…systematic review and meta-analysis has suggested an association between clozapine treatment and significantly more abstinence from (time without consume of) substance use and lower rates of psychiatric hospitalization, compared with other first-and second-generation antipsychotic medications [55].”
ResultChiappini, S., Cavallotto, C., Mosca, A., Carlo, F. D., Piro, T., Giovannetti, G., Pasino, A., Vicinelli, M. C., Lorenzini, C., Paolo, M. D., et al. (2024) · Pharmaceuticals · doi:10.3390/ph17040535 · Cited by 34
“Specifically, according to recent studies, clozapine treat-ment is linked to markedly higher chances of maintaining abstinence from substance use and a reduced probability of psychiatric hospitalization in comparison to continued treat-ment with other antipsychotic medications [27,28].”
Background
Metadata
- Authors
- Rafizadeh, R., Danilewitz, M., Bousman, C. A., Mathew, N., White, R. F., Bahji, A., Honer, W. G., & Schütz, C. G.
- Affiliations
- University of British Columbia (CA)
- University of Toronto (CA)
- University of Calgary (CA)
- Corresponding author
- Rafizadeh, Reza
- ORCID
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2022-12-12
- Volume
- 37
- Issue
- 2
- Pages
- 135-143
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- PMC
- PMC9912304
- OpenAlex
- W4311204828
- Cited by
- 41
- References
- 55
- Citations by year
- 2026: 12 · 2025: 16 · 2024: 9 · 2023: 4
- FWCI
- 1.25
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Psychopharmacology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- National Institute on Drug Abuse (R25DA037756)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Social Sciences › Arts and Humanities › Philosophy › Mental Health and Psychiatry
- Keywords
- clozapine, substance use disorders, schizophrenia spectrum disorders, alcoholism, abstinence, psychiatric hospitalization, antipsychotic drugs, comorbidities, treatment-resistant psychosis
- MeSH terms
- Clozapine, Female, Humans, Male, Nicotine, Schizophrenia, Antipsychotic Agents, Substance-Related Disorders, Observational Studies as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

